Misplaced Pages

Dordaviprone

Clinical data
Other names	ONC-201
Legal status
Legal status	Investigational
Identifiers
IUPAC name 11-benzyl-7--2,5,7,11-tetrazatricyclotrideca-1(9),5-dien-8-one
CAS Number	1616632-77-9
PubChem CID	73777259
DrugBank	DB14844
ChemSpider	30904994
UNII	9U35A31JAI
KEGG	D12733
ChEBI	CHEBI:232328
ChEMBL	ChEMBL4297310
Chemical and physical data
Formula	C24H26N4O
Molar mass	386.499 g·mol
3D model (JSmol)	Interactive image
SMILES CC1=CC=CC=C1CN2C(=O)C3=C(CCN(C3)CC4=CC=CC=C4)N5C2=NCC5
InChI InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3 Key:VLULRUCCHYVXOH-UHFFFAOYSA-N

Dordaviprone is an investigational new drug that is being evaluated for the treatment of diffuse intrinsic pontine glioma (a type of brain tumor). It is dopamine receptor D2 antagonist and an allosteric activator of the mitochondrial caseinolytic protease P.

References

1. "Dordaviprone - Chimerix". AdisInsight. Springer Nature Switzerland AG.
2. Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, et al. (December 2020). "ONC201 and imipridones: Anti-cancer compounds with clinical efficacy". Neoplasia. 22 (12). New York, N.Y.: 725–744. doi:10.1016/j.neo.2020.09.005. PMC 7588802. PMID 33142238.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Imidazopyrimidines
• Pharmacology stubs